Evaluating NF2 and Other Tumor Disease Mechanisms

The objective is to share patient skin derived fibroblasts, induced Schwann cells as well as tumor cells between CBTT and Nationwide Children’s Hospital. Dr. Meyer’s lab will have access to frozen tumor samples as well as tumor cell lines from NF2 patients and patients suffering from other forms of cancer through CBTTC. The samples are highly valuable to us to study disease mechanisms and treatments in the context of various mutations. The Meyer lab is also receiving skin biopsies from NF2 patients which NCH is willing to share with CBTTC under MTA. We might also receive additional tumor samples from Ohio State or NCH, but as we are investigating patient specific molecular mechanisms, these samples do not represent an overlap.